Advances in aptamer-mediated targeted delivery system for cancer treatment

Int J Biol Macromol. 2023 May 31:238:124173. doi: 10.1016/j.ijbiomac.2023.124173. Epub 2023 Mar 23.

Abstract

Aptamers with high affinity and specificity for certain targets have rapidly become a novel class of targeted ligands applicated in drug delivery. Based on the excellent characteristics of aptamers, different aptamer-mediated drug delivery systems have been developed, including aptamer-drug conjugate (ApDC), aptamer-siRNA, and aptamer-functionalized nanoparticle systems for the effective treatment of cancer, which can reduce potential toxicity and improve therapeutic efficacy. In this review, we summarize the recent progress of aptamer-mediated delivery systems in cancer therapy, and discuss the application prospects and existing problems of innovative approaches based on aptamer therapy. Overall, this review aims to better understand the current aptamer-based targeted delivery applications through in-depth analysis to improve efficacy and develop new therapeutic methods which can ultimately improve treatment outcomes for cancer patients.

Keywords: Aptamer-drug conjugate; Cancer therapy; Targeted delivery; siRNA.

Publication types

  • Review

MeSH terms

  • Aptamers, Nucleotide*
  • Drug Delivery Systems / methods
  • Humans
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / therapeutic use

Substances

  • Aptamers, Nucleotide
  • RNA, Small Interfering